3 results
Approved WMORecruiting
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues
Approved WMOCompleted
Primary objective:To assess the clinical activity of AL101 using radiographic assessments and RECIST v1.1 in ACC patients with activating Notchmutations.Secundary objectives:• To assess quality of life in ACC patients with activating mutations.• To…
Approved WMORecruiting
This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed.